Read More

Reported Late Monday, Graybug And CalciMedica Enter Into Definitive Merger Agreement To Combine The Companies In An All-Stock Transaction; The Combined Company Will Focus On Further Developing CalciMedica’s Lead Product Candidate Auxora

– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory

GRAY